title: (18)F-FDG PET/CT for the assessment of myocardial sarcoidosis.
abstract: Cardiac involvement portends a poor prognosis in patients with sarcoidosis. However, due to the nonspecific clinical manifestations of the disease, patchy myocardial involvement, and the limited diagnostic yield of diagnostic tests, early diagnosis of cardiac sarcoidosis has been exceedingly difficult. As a result, there is no standardized approach for the early diagnosis of cardiac sarcoidosis. Imaging modalities that can both identify disease and predict response to therapy are paramount to improve management of cardiac sarcoidosis. (18)F-FDG PET has many practical advantages in assessing disease activity and monitoring treatment response in patients with cardiac sarcoidosis. Accumulating data support the growing role of (18)F-fluorodeoxyglucose ((18)F-FDG) PET in the diagnosis and risk stratification of patients with cardiac sarcoidosis.
authors.affiliation: Department of Radiology, Division of Nuclear Medicine and Molecular imaging, 70 Francis Street, Shapiro 5th Floor, Room 128, Boston, MA 02115, USA.
authors.forename: Hicham
authors.initials: H
authors.lastname: Skali
authors.forename: Allison R
authors.initials: AR
authors.lastname: Schulman
authors.forename: Sharmila
authors.initials: S
authors.lastname: Dorbala
mesh_terms: D009202:Cardiomyopathies / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000503:physiopathology; D019788:Fluorodeoxyglucose F18; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007090:Image Interpretation, Computer-Assisted / Q000379:methods; D064847:Multimodal Imaging / Q000379:methods; D049268:Positron-Emission Tomography; D011379:Prognosis; D019275:Radiopharmaceuticals; D012507:Sarcoidosis / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000503:physiopathology; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D005938:Glucocorticoids; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18